CEO Dave Rosa said, “As we look ahead, we are reiterating our fiscal year 2025 guidance, with product revenues expected to increase to between $8M-$10M, representing an increase of between 132%-190% when compared to product revenue of $3.5M in fiscal year 2024, and expanded product gross margin of between 47%-51%, compared to product gross margin of 31% in fiscal year 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMTC:
- NeuroOne Medical’s OneRF technology featured in Fox News story
- NeuroOne Medical 16M share Spot Secondary priced at 50c
- NeuroOne Medical prices 16M shares at 50c in underwritten public offering
- NeuroOne Medical announces common stock offering, no amount given
- NeuroOne accelerates timeline of submission for OneRF trigeminal nerve ablation